Key Takeaways Cytokinetics reported a Q4 loss of $1.50 per share as operating expenses climbed year over year.CYTK gained FDA approval for Myqorzo in oHCM, with EU and China nods and Germany launch set for Q2 2026.Cytokinetics ended 2025 with $1.22B in cash as multiple late-stage aficamten studies advance globally.Cytokinetics (CYTK) reported a net loss of $1.50 per share for the fourth quarter of 2025, wider than the Zacks Consensus Estimate of a loss of $1.48. In the year-ago quarter, the company reported ...

Cytokinetics (NasdaqGS:CYTK) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Company ParticipantsAlex Xenakis - Research AssociateAndrew Callos - EVP and CCOCory Kasimov - Senior Managing DirectorDiane Weiser - SVP of Corporate Communications and Investor RelationsFady Malik - EVP of Research and DevelopmentJackie Plesset - SMid Cap Biotech Equity Research AssociateJames Condulis - VP of Biotechnology Equity ResearchJoe Pantginis - Managing Director Equity ResearchMaxwell Skor - VP of Biotech Equity Res ...

Cytokinetics (NasdaqGS:CYTK) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Company ParticipantsAndrew Callos - EVP and CCOCory Kasimov - Senior Managing DirectorDiane Weiser - SVP of Corporate Communications and Investor RelationsFady Malik - EVP of Research and DevelopmentJackie Plesset - SMid Cap Biotech Equity Research AssociateJames Condulis - VP of Biotechnology Equity ResearchJoseph Pantginis - Managing Director Equity ResearchMaxwell Skor - VP of Biotech Equity ResearchMayank Mamtani - Senior M ...

Cytokinetics (NasdaqGS:CYTK) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Speaker13Thank you for standing by. Welcome to the Cytokinetics Fourth Quarter 2025 Earnings Call. This call is being recorded. All participants are in a listen-only mode. After the speaker's remarks, we will open the call to questions. We will allow for one question per participant. If you would like to ask a question during this time, simply press star followed by 1 on your telephone keypad. If you'd like to withdraw your que ...

MYQORZO® Approved for Adults with Symptomatic Obstructive HCM in U.S., China and Europe; U.S. Launch Underway with First Prescriptions Dispensed within Days of Drug Availability Supplemental NDA for MAPLE-HCM Submitted to FDA in Q1 2026 Expect to Share Topline Results from ACACIA-HCM in Q2 2026 Company Provides 2026 Financial Guidance;~$1.2 Billion in Cash, Cash Equivalents and Investments as of December 31, 2025 SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasd ...

Core Insights - Cytokinetics is set to report its fourth quarter results on February 24, 2026, at 4:00 PM Eastern Time, followed by a conference call at 4:30 PM to discuss financial results and business updates [1][2] Company Overview - Cytokinetics is a specialty cardiovascular biopharmaceutical company with over 25 years of experience in muscle biology, focusing on developing new medicines for cardiac muscle dysfunction [3] - The company’s MYQORZO™ (aficamten) is approved for treating adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM) and has received positive recommendations for marketing authorization in the European Union, with a decision expected in the first quarter of 2026 [3] - Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for heart failure with severely reduced ejection fraction, and ulacamten, an investigational cardiac myosin inhibitor for heart failure with preserved ejection fraction [3]

Core Insights - Cytokinetics has awarded grants to two patient advocacy organizations to enhance communication and community outreach for hypertrophic cardiomyopathy (HCM) [2][3] Group 1: Grant Recipients and Initiatives - Camp Taylor received a grant to produce "Living with HCM: Youth Voices from Camp Taylor," a digital initiative that includes a five-part video series and an information toolkit aimed at educating families about HCM [4] - The Canadian Sudden Arrhythmia Death Syndromes (SADS) Foundation will develop "Think. Know. Act.: Cardiomyopathy Awareness in Canada," a six-month digital campaign to raise awareness of HCM symptoms and management among Canadian families [5] Group 2: Purpose and Impact of the Grant Program - The Cytokinetics Communications Grant Program aims to support patient advocacy organizations by providing resources for communications and outreach initiatives that are otherwise difficult to implement [6] - The program has been active for eight years, focusing on increasing awareness and community engagement for patient communities [6] Group 3: Company Overview - Cytokinetics is a specialty cardiovascular biopharmaceutical company with over 25 years of experience in muscle biology and a pipeline of potential new medicines for cardiac muscle dysfunction [7] - The company’s product MYQORZO™ (aficamten) is approved for treating adults with symptomatic obstructive HCM, with positive opinions for marketing authorization in the European Union expected in early 2026 [7][8]

Market Overview - The Heart Failure Drugs Market is valued at USD 8.80 Billion in 2025 and is projected to reach USD 28.29 Billion by 2033, growing at a CAGR of 15.73% from 2026 to 2033 [1][7][20] - The U.S. Heart Failure Drugs Market is estimated at USD 2.54 Billion in 2025 and expected to grow to USD 8.03 Billion by 2033, with a CAGR of 15.47% during the same period [3] Market Drivers - The growth of the heart failure medications market is primarily driven by demographic trends, particularly the aging population, which increases the risk of heart failure and cardiovascular diseases [2][8] - The rising prevalence of lifestyle-related conditions such as hypertension, diabetes, and obesity is contributing to the increased demand for heart failure treatments [2][8] Market Segmentation - By Type: ACE Inhibitors hold the largest market share at 34.80%, while Beta Blockers are the fastest-growing segment with a CAGR of 12.90% [10] - By Application: Tablets lead the market with a 49.60% share, while injections are the fastest-growing segment with a CAGR of 11.70% [11] - By Distribution Channel: Hospital Pharmacies dominate with a 45.20% share, and Online Pharmacies are the fastest-growing segment with a CAGR of 14.80% [15] Regional Insights - North America accounted for over 40.65% of the Heart Failure Drugs Market in 2025, driven by high prevalence of cardiovascular diseases and advanced healthcare infrastructure [17] - The Asia Pacific region is expected to grow at the fastest rate with a CAGR of 16.81%, fueled by increasing cardiovascular disease prevalence and improving healthcare access [17] Recent Developments - Bayer AG received FDA approval for its drug Kerendia (finerenone) in July 2025, targeting heart failure patients with left ventricular ejection fraction (LVEF) ≥40% [21] - Cytokinetics launched a Phase 3 trial for omecamtiv mecarbil in December 2024, focusing on patients with symptomatic heart failure and severely reduced ejection fraction [21]

Core Insights - Cytokinetics has launched the "On Track with HCM" campaign to support the hypertrophic cardiomyopathy (HCM) community, featuring Sydney McLaughlin-Levrone and her father, Willie McLaughlin, who has lived with HCM for over two decades before receiving a heart transplant [1][2]. Company Commitment - The campaign is designed in collaboration with the HCM patient advocacy community to assist patients in managing the symptoms of HCM in their daily lives [2][4]. - Cytokinetics aims to address both clinical care and the human experience of living with HCM, empowering patients and their families to lead healthier lives [4]. HCM Overview - HCM is the most common inherited heart disease, affecting approximately 1 in every 350 people in the U.S., with many remaining undiagnosed [3][7]. - The disease can lead to serious complications such as atrial fibrillation, heart failure, and sudden cardiac arrest [3][6]. Educational Resources - The "On Track with HCM" program includes a website and eight original videos that share personal experiences and expert insights on managing HCM [2][4]. - The content covers various aspects of living with HCM, including fitness, nutrition, and the mind-body connection [5]. Cytokinetics' Product Pipeline - Cytokinetics is advancing its pipeline of potential new medicines for cardiac muscle dysfunction, including MYQORZO™ (aficamten), which is approved for treating symptomatic obstructive HCM [8]. - The company is also developing other investigational treatments for heart failure and continues research in muscle biology [8].

Core Insights - Cytokinetics, Incorporated will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 9:45 AM Pacific Time [1] Company Overview - Cytokinetics is a specialty cardiovascular biopharmaceutical company with over 25 years of experience in muscle biology, focusing on developing new medicines for cardiac muscle dysfunction [3] - The company’s product MYQORZO™ (aficamten) is approved for treating adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM) by the U.S. FDA and the China National Medical Products Administration [3] - The European Medicines Agency has adopted a positive opinion for MYQORZO™ (aficamten), with a decision from the European Commission expected in Q1 2026 [3] - Cytokinetics is also developing omecamtiv mecarbil for heart failure with severely reduced ejection fraction and ulacamten for heart failure with preserved ejection fraction, alongside ongoing pre-clinical research in muscle biology [3]